Soligenix Inc. (NASDAQ: SNGX) announced it has enrolled 50 of the planned 80 patients in its confirmatory Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE